Cargando…
Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activity.
Cisplatin is one of the most active cytotoxic agents in the treatment of testicular cancer, but its clinical use is associated with side-effects such as ototoxicity, neurotoxicity and nephrotoxicity. Long-term kidney damage from cisplatin particularly affects the proximal tubular apparatus and can b...
Autores principales: | Bokemeyer, C., Fels, L. M., Dunn, T., Voigt, W., Gaedeke, J., Schmoll, H. J., Stolte, H., Lentzen, H. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1996
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074813/ https://www.ncbi.nlm.nih.gov/pubmed/8980410 |
Ejemplares similares
-
The anti-tumour activity of ifosfamide on heterotransplanted testicular cancer cell lines remains unaltered by the uroprotector mesna.
por: Bokemeyer, C., et al.
Publicado: (1994) -
5-Aminolevulinic Acid Protects against Cisplatin-Induced Nephrotoxicity without Compromising the Anticancer Efficiency of Cisplatin in Rats In Vitro and In Vivo
por: Terada, Yoshio, et al.
Publicado: (2013) -
Mechanisms of Cisplatin Nephrotoxicity
por: Miller, Ronald P., et al.
Publicado: (2010) -
Prevention of cisplatin nephrotoxicity
por: Hayati, Fatemeh, et al.
Publicado: (2015) -
The pseudoginsenoside F11 ameliorates cisplatin-induced nephrotoxicity without compromising its anti-tumor activity in vivo
por: Wang, Hongbo, et al.
Publicado: (2014)